AKTIENANLEIHE - DERMAPHARM HOLDING Share Price

Certificat

DE000DQ0SWS4

Market Closed - Boerse Frankfurt Warrants 01:04:19 29/05/2024 am IST
99.11 EUR -0.09% Intraday chart for AKTIENANLEIHE - DERMAPHARM HOLDING
Current month+4.91%
1 month+4.34%
Date Price Change
28/24/28 99.11 -0.09%
27/24/27 99.2 +0.14%
24/24/24 99.06 -0.19%
23/24/23 99.25 -0.04%
22/24/22 99.29 +0.91%

Real-time Boerse Frankfurt Warrants

Last update May 29, 2024 at 01:04 am IST

More quotes

Static data

Product typeReverse Convertibles
Buy / SellCALL
Underlying DERMAPHARM HOLDING SE
Issuer DZ BANK
WKN DQ0SWS
ISINDE000DQ0SWS4
Date issued 20/02/2024
Strike 30
Maturity 20/12/2024 (206 Days)
Parity 0.03 : 1
Emission price 100
Emission volume N/A
Settlement both
Currency EUR

Technical Indicators

Highest since issue 100.4
Lowest since issue 94.47

Company Profile

Dermapharm Holding SE is a Germany-based company engaged in manufacturing of patent-free branded pharmaceuticals. The Company operates through two segments: Branded pharmaceuticals and other healthcare products, which includes in-house development, in-house production, and distribution of branded pharmaceuticals and other healthcare products, and Parallel import business, which operates under the axicorp brand. It holds around 950 marketing authorizations for more than 250 active pharmaceutical ingredients, which are marketed as pharmaceuticals, dietary supplements or supplemental balanced diets. The Company offers its products through a number of brands, including Dekristol, Ampho Moronal, Keltican, Tromcardin, among others. It is active primarily in Germany, Switzerland and Austria. Additionally, it operates production facility in Germany. Trommsdorff & GmbH Co KG is a subsidiary of the Company.
Sector
-
More about the company

Ratings for Dermapharm Holding SE

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Consensus: Dermapharm Holding SE

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
36.9 EUR
Average target price
56.9 EUR
Spread / Average Target
+54.20%
Consensus